Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

William W Busse, Pierluigi Paggiaro, Xavier Muñoz, Thomas B Casale, Mario Castro, G Walter Canonica, Jo A Douglass, Yuji Tohda, Nadia Daizadeh, Benjamin Ortiz, Nami Pandit-Abid, William W Busse, Pierluigi Paggiaro, Xavier Muñoz, Thomas B Casale, Mario Castro, G Walter Canonica, Jo A Douglass, Yuji Tohda, Nadia Daizadeh, Benjamin Ortiz, Nami Pandit-Abid

Abstract

Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD

Trial registration: ClinicalTrials.gov NCT02414854.

Conflict of interest statement

Conflict of interest: W.W. Busse is a consultant for AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Inc. and Sanofi; and is on the data safety monitoring board for Boston Scientific. Conflict of interest: P. Paggiaro received research grants and is an advisory board member for AstraZeneca, Chiesi, GlaxoSmithKline, Novartis and Sanofi. Conflict of interest: X. Muñoz is a speaker, scientific advisor for and has received clinical trial investigator fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Faes Farma, GlaxoSmithKline, Menarini, Mundipharma, Novartis and Teva. Conflict of interest: T.B. Casale received research support from American Lung Association, Genentech, NIH, Novartis, PCORI and Sanofi; is a consultant for AstraZeneca, Boehringer Ingelheim, Genentech, Novartis and Regeneron Pharmaceuticals, Inc.; is on the speakers bureau of Genentech. Conflict of interest: M. Castro received research support from American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis and Shionogi; is a consultant for Genentech, Novartis, sanofi-aventis and Teva; received speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi and Teva; received royalties from Elsevier. Conflict of interest: G.W. Canonica received speaker fees and is an advisory board member of ALK, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HAL Allergy, Menarini, Mundipharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Stallergenes Greer and Uriach. Conflict of interest: J.A. Douglass received research funding, speaker fees and is an advisory board member of AstraZeneca, GlaxoSmithKline, Novartis and Sanofi. Conflict of interest: Y. Tohda is a consultant for AstraZeneca, Kyorin Pharmaceuticals and Sanofi. Conflict of interest: N. Daizadeh is an employee of and may hold stock and/or stock options in Sanofi. Conflict of interest: B. Ortiz is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Conflict of interest: N. Pandit-Abid is an employee of and may hold stock and/or stock options in Sanofi.

Figures

FIGURE 1
FIGURE 1
a) Adjusted annualised severe exacerbation rate. b) Least squares (LS) mean difference in the change in pre-bronchodilator forced expiratory volume in 1 s (FEV1) from baseline at week 12 between dupilumab and placebo by baseline patient demographic and disease characteristic subgroup. BMI: body mass index; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroids; LABA: long-acting β2-agonists; ppb: parts per billion.
FIGURE 1
FIGURE 1
a) Adjusted annualised severe exacerbation rate. b) Least squares (LS) mean difference in the change in pre-bronchodilator forced expiratory volume in 1 s (FEV1) from baseline at week 12 between dupilumab and placebo by baseline patient demographic and disease characteristic subgroup. BMI: body mass index; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroids; LABA: long-acting β2-agonists; ppb: parts per billion.

References

    1. Chung KF, Wenzel SE, Brozek JL, et al. . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. doi:10.1183/09031936.00202013
    1. Zein JG, Denson JL, Wechsler ME. Asthma over the adult life course: gender and hormonal influences. Clin Chest Med 2019; 40: 149–161. doi:10.1016/j.ccm.2018.10.009
    1. Khalid F, Holguin F. A review of obesity and asthma across the life span. J Asthma 2018; 55: 1286–1300. doi:10.1080/02770903.2018.1424187
    1. Harrison TW, Chanez P, Menzella F, et al. . Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 2021; 9: 260–274. doi:10.1016/S2213-2600(20)30414-8
    1. Sposato B, Scalese M, Latorre M, et al. . Effects of omalizumab in severe asthmatics across ages: a real life Italian experience. Respir Med 2016; 119: 141–149. doi:10.1016/j.rmed.2016.09.005
    1. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol 2015; 15: 57–65. doi:10.1038/nri3786
    1. Macdonald LE, Karow M, Stevens S, et al. . Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA 2014; 111: 5147–5152. doi:10.1073/pnas.1323896111
    1. Murphy AJ, Macdonald LE, Stevens S, et al. . Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 2014; 111: 5153–5158. doi:10.1073/pnas.1324022111
    1. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 2017; 13: 425–437. doi:10.1080/1744666X.2017.1298443
    1. Wenzel S, Castro M, Corren J, et al. . Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388: 31–44. doi:10.1016/S0140-6736(16)30307-5
    1. Castro M, Corren J, Pavord ID, et al. . Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486–2496. doi:10.1056/NEJMoa1804092
    1. Rabe KF, Nair P, Brusselle G, et al. . Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475–2485. doi:10.1056/NEJMoa1804093
    1. Agache I, Akdis CA, Akdis M, et al. . EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy 2021; 76: 14–44. doi:10.1111/all.14425
    1. Agache I, Song Y, Rocha C, et al. . Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1058–1068. doi:10.1111/all.14268
    1. Doroudchi A, Pathria M, Modena BD. Asthma biologics: comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol 2020; 124: 44–56. doi:10.1016/j.anai.2019.10.016

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever